Impact of intermittent preventive treatment with sulfadoxine-pyrimethamine on antibody responses to erythrocytic-stage Plasmodium falciparum antigens in infants in Mozambique.
We evaluated the impact of intermittent preventive treatment in infants (IPTi) with sulfadoxine-pyrimethamine (SP), which was given at ages 3, 4, and 9 months through the Expanded Program on Immunization (EPI), on the development of antibody responses to Plasmodium falciparum in Mozambique. Immunoglobulin M (IgM) and IgG subclass antibodies specific to whole asexual parasites and to recombinant MSP-1(19), AMA-1, and EBA-175 were measured at ages 5, 9, 12, and 24 months for 302 children by immunofluorescence antibody tests and by enzyme-linked immunosorbent assays. Antibody responses did not significantly differ between children receiving IPTi with SP and those receiving a placebo at any time point measured, with the exception of the responses of IgG and IgG1 to AMA-1 and/or MSP-1(19), which were significantly higher in the SP-treated group than in the placebo group at ages 5, 9, and/or 24 months. IPTi with SP given through the EPI reduces the frequency of malarial illness while allowing the development of naturally acquired antibody responses to P. falciparum antigens.
Quelhas
Diana
D
Centro de Investigação em Saúde da Manhiça (CISM), Manhiça, Mozambique.
Puyol
Laura
L
Quintó
Llorenç
L
Serra-Casas
Elisa
E
Nhampossa
Tacilta
T
Macete
Eusebio
E
Aide
Pedro
P
Mayor
Alfredo
A
Mandomando
Inacio
I
Sanz
Sergi
S
Aponte
John J
JJ
Chauhan
Virander S
VS
Chitnis
Chetan E
CE
Alonso
Pedro L
PL
Menéndez
Clara
C
Dobaño
Carlota
C
D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood*; D000953:Antigens, Protozoan / Q000235:genetics / Q000276:immunology*; D000962:Antimalarials / Q000008:administration & dosage / Q000627:therapeutic use; D002675:Child, Preschool; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004912:Erythrocytes / Q000469:parasitology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007223:Infant; D016778:Malaria, Falciparum / Q000276:immunology / Q000517:prevention & control*; D009073:Mozambique; D010963:Plasmodium falciparum / Q000276:immunology*; D011739:Pyrimethamine / Q000008:administration & dosage / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology; D013413:Sulfadoxine / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D000962:Antimalarials; D004338:Drug Combinations; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D011994:Recombinant Proteins; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D011739:Pyrimethamine